Tirzepatide, a novel medication known for its benefits in diabetes management, has shown promising potential as a treatment for NAFLD, offering hope for individuals struggling with this condition
Safety notes: Contraindicated in individuals with a personal history of cancer, uncontrolled diabetes, significant cardiovascular disease, or untreated sleep apnea
A repeat of meta-analysis using a high dose of a GLP-1 analogue (liraglutide 1.8 mg) showed a significant reduction in total cholesterol compared to sitagliptin: mean difference 0.16 mmol/L (0.25 to 0.06, I 2 = 0%, P = 0.63)
Average weight loss is greater and side effects tend to be a little milder. FAQs Is tirzepatide more effective than semaglutide
Carolynn Francavilla Brown, a physician and vice president of the Obesity Medicine Association, the nation's largest medical organization for clinicians dedicated to preventing and treating the condition
Unknown effects from extended or repeated use cannot be ruled out